Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Moore Highlights Hope for Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

August 25th 2020

In an interview with OncLive, Kathleen Moore, MD, discusses the MIRASOL trial and the hope for mirvetuximab soravtansine in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high FRα expression.

Dr. Liu on Cediranib/Olaparib in Recurrent Ovarian Cancer

August 14th 2020

Joyce F. Liu, MD, MPH, discusses the results of cediranib in combination with olaparib in a phase 3 trial in patients with recurrent platinum-sensitive ovarian cancer.

Dr. Matulonis on CPS as a Potential Biomarker in Advanced Recurrent Ovarian Cancer

August 13th 2020

Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.

Phase 3 OVAL Trial With VB-111 in Platinum-Resistant Ovarian Cancer to Continue

August 12th 2020

The independent data safety monitoring committee has unanimously recommended that the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer continue as planned.

Dr. Monk on Emerging Therapies in Cervical Cancer

August 11th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses emerging therapies in cervical cancer.

Dizon Discusses Elements of Sexual Health in Gynecologic Cancer

August 6th 2020

In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.

Dr. Westin on Challenges With Precision Medicine in Endometrial Cancer

August 4th 2020

Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer.

Dr. Mirza on Final Data of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer

August 3rd 2020

Mansoor Raza Mirza, MD, discusses the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Blood Spectroscopy Could Detect Early Endometrial Cancer Diagnoses

July 30th 2020

Blood spectroscopy testing could be a faster, more accurate, less-invasive, and more cost-effective method for testing and diagnosing women with the early stages of endometrial cancer.

Monk Magnifies Emerging Approaches Making Headway in Cervical Cancer Management

July 29th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses key updates in cervical cancer treatment, exciting ongoing research efforts, and emerging approaches that are shaking up the treatment paradigm.

Dr. Monk on the Importance of Early Pap Testing in Cervical Cancer

July 27th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of Pap testing early on in cervical cancer.

Dr. Monk on the Limitations of Current Treatment in Metastatic/Recurrent Cervical Cancer

July 24th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.

ATHENA Trial of Maintenance Rucaparib/Nivolumab in Ovarian Cancer Completes Target Enrollment

July 23rd 2020

The pivotal phase 3 ATHENA trial, which will examine the safety and efficacy of rucaparib in combination with nivolumab as maintenance treatment following response to front-line platinum-based chemotherapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, has completed target enrollment.

USC73 Score Predictive of OS in Uterine Serous Carcinoma

July 23rd 2020

A 73-gene proliferative transcriptomic signature was found to better predict overall survival outcomes and potentially be used to personalize treatment in patients with uterine serous carcinoma.

Dr. Slomovitz on the Role of Surgery in Endometrial Cancer

July 15th 2020

Brian M. Slomovitz, MD, discusses the role of surgery in women with endometrial cancer.

Phase 3 IMagyn050 Trial in Ovarian Cancer Does Not Meet Primary End Point of PFS

July 13th 2020

Results from the phase 3 IMagyn050 trial showed that the addition of atezolizumab to bevacizumab, paclitaxel, and carboplatin did not meet the primary end point of progression-free survival for first-line treatment of women with newly diagnosed, advanced ovarian cancer.

Dr. Salani on the Current State of Biomarker Testing in Cervical Cancer

July 8th 2020

Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.

Yale Cancer Center Study Validates Combination Therapy for Aggressive Endometrial Cancer

July 8th 2020

Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.

Dr. Monk on the Utility of Tisotumab Vedotin in Recurrent Cervical Cancer

July 1st 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.

Tisotumab Vedotin Shows Favorable Activity in Recurrent or Metastatic Cervical Cancer

June 30th 2020

The antibody-drug conjugate tisotumab vedotin induced clinically meaningful and durable responses in patients who have relapsed or progressed on or after previous treatment for recurrent or metastatic cervical cancer.